Ministers and representatives from twelve African countries have committed themselves, and laid out their plans, to end AIDS in children by 2030. International partners have set out how they would support countries in delivering on those plans.
The government of Singapore has announced a pledge of US$1 million to the Global Fund, recognizing the need for sustained financial support for countries and communities to fight AIDS, tuberculosis and malaria and strengthen systems for health.
The Global Fund to Fight AIDS, Tuberculosis and Malaria and private sector partners officially launched the Digital Health Impact Accelerator (DHIA), a US$50 million catalytic fund designed to accelerate countries’ digital health transformation in su...
The Global Fund to Fight AIDS, Tuberculosis and Malaria has committed US$20 million to Pakistan and US$1.9 million to Somalia in emergency funding to support the health systems faced with climate change disasters. Massive flooding in Pakistan has led...
The Government of India has announced an increased commitment of US$25 million to the Global Fund for the next three years, highlighting India’s leadership in global efforts to end AIDS, TB and malaria and to build stronger health systems.
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria welcomed the Seventh Replenishment outcome of US$15.7 billion during a 3-day meeting this week in Geneva. This comes two months after a successful pledging conference in New York th...
The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds today’s announcement by Italy of a €185 million pledge for the upcoming three-year period to help the world get back on track to end HIV, TB and malaria as public health threats by 2030...
The Global Fund warmly welcomes the decision by the United Kingdom to renew its strong commitment to help end AIDS, tuberculosis and malaria and strengthen health and community systems around the world. Minister for Development Andrew Mitchell announ...
The Global Fund to Fight AIDS, TB and Malaria has signed an agreement with Pfizer for the procurement of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website.
To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.